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Abstract
The future of personalized oncological therapy will likely rely on evidence-based medicine to integrate all of the
available evidence to delineate the most efficacious treatment option for the patient. To undertake evidence-based
medicine through use of targeted therapy regimens, identification of the specific underlying causative mutation(s)
driving growth and progression of a patient’s tumor is imperative. Although molecular subtyping is important for
planning and treatment, intraclonal genetic diversity has been recently highlighted as having significant implica-
tions for biopsy-based prognosis. Overall, delineation of the clonal architecture of a patient’s cancer and how this
will impact on the selection of the most efficacious therapy remain a topic of intense interest.
Neoplasia (2013) 15, 1410–1420
Introduction
In the early 1600s, Miguel de Cervantes wrote the book titled
Don Quixote during the historical period known as the Spanish Golden
Age. In the book, the protagonist Alonso Quijano, an older gentle-
man with waning mental facilities, dons a suit of armor and renames
himself “Don Quixote de la Mancha.” Early one morning at dawn,
Don Quixote rides off on his trusted horse “Rocinante” along with
his neighbor Sancho Panza whom he asked to be his squire. Together,
they experience a series of (mis)adventures. In one particularly famous
episode described in the novel, they came on a vast plain dotted with
a myriad of windmills wherein Don Quixote, on seeing them, said to
his squire, “Fortune is guiding our affairs better than we ourselves
could have wished. Do you see over yonder, friend Sancho, thirty or
forty hulking giants? I intend to do battle with them and slay them.
With their spoils we shall begin to be rich for this is a righteous war
and the removal of so foul a brood from off the face of the earth is a
service God will bless.” Sancho Panza replied to his trusted master,
“What giants?” “Those you see over there,” replied his master, “with
their long arms. Some of them have arms well-nigh two leagues in
length.” Don Quixote imagined the windmills to be giants with large
arms in the distance and proceeded to fight the giants to rid humanity
of their scourge.
The imagery provided by Cervantes is quite interesting and relevant
for cancer researchers as Don Quixote consistently misinterpreted his
adversaries and actions of his allies. Misinterpretation of the enemy
targets resulted in consequences that expended resources that were
not productive in achieving the overarching goal. Viewed as an allegory
for cancer research, one can envision the hub of the windmill as the
original mutation within an individual cell and each of the windmill
blades as multiple cancers emerging of this initiating event due to
genetic heterogeneity. This process results in a diverse set of cell popu-
lations emanating out from the “hub” of the original cell mutation.
Thus, each patient may have a completely different set of cancers
(blades on the windmill) due to the overall chaotic processes.
This past year, technological advances in measuring intratumor can-
cer diversity revealed significant differences between cancerous cells
within a patient [Potter NE, Ermini L, Papaemmanuil E, Cazzaniga
G, Vijayaraghavan G, Titley I, Ford A, Campbell P, Kearney L,
Greaves M (2013). Single-cell mutational profiling and clonal phylog-
eny in cancer. Genome Res 23(12), 2115–2125]. Investigators at the
Institute of Cancer Research quantified cancer diversity within five
different patients with leukemia. When the mutations were compared
in individual tumor cells against a known database, it was determined
that patients had not 1 but between 2 and 10 genetically distinct
leukemias. Thus, each of the patients was found to not have a single
cancer but multiple cancers much like the windmill analogy with
multiple blades. In fact, it appears that treatment of patients with cancer
will require that their disease be considered as multiple cancers each
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needing its own unique intervention. In other words, not only will the
hub need to be treated but also each of the “blades” emanating out from
the initiating cell will also need to be targeted to have a lasting cure. In
fact, although it is currently unclear how many different cancers a solid
tumor may have, it could increase many-fold, and each patient will
likely have a different number that will require treatment. Advances
in technology are beginning to transform our understanding and
capabilities by providing an opportunity to undertake a comprehensive
interrogation of the complex genomics within a tumor using single-cell
analysis. Whole-genome amplification of single cells obtained from
the tumor of a patient allowing for subclonal information to be derived
will likely be proven as a significant advance in our quest for if not an
outright cure, then at least significantly prolonged survival with a good
quality of life.
Summary
The overall economic burden of cancer is huge and was recently as-
sessed across the European Union using a population-based cost
analysis (Luengo-Fernandez et al., Lancet Oncology, 14(12):1165-
74, 2013). The overall cancer cost was estimated to be in the
$170 billion range annually. These numbers clearly indicate that
we cannot afford to continue to charge at windmills but need to be-
gin to carefully assess how best to focus our attention and resources.
Areas might include targeting tumor vasculature, stimulation of the
immune system, or early diagnosis or a combination. It seems clear
that, likely, each patient has a unique and complex array of diverse
mutations, each of which must be treated to gain optimal therapeutic
control. In this regard, improving our understanding of cancer biol-
ogy in the context of genotypic and phenotypic diversity is required
to positively impact outcomes of patients with cancer. The mission
of the journal Neoplasia is to provide peer-reviewed information re-
lated to advancing knowledge and clinical care of oncology patients.
In this regard, we have published a diverse array of articles on topics
related to tumor biology, genetics, experimental therapeutics, clinical
investigations, and cancer imaging (Table 1). The dissemination of
this broad-based information will assist researchers with their efforts
in adding continuously to the progressing story. Neoplasia provides
rapid access to all articles to the worldwide clinical cancer research
community, which is a key feature of this journal. As the Editor
along with my esteemed members of the Editorial Board, together
we are very pleased with the success that this effort has had in serving
the cancer research community and look forward to continued prog-
ress in improving the outcome of patients diagnosed with cancer.
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